Protalix BioTherapeutics Long Term Debt

As of the most recent data (June 2026), PLX shows a long-term debt of $7.5M. That compares with $3.9M in the prior-year period — up 94.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PLX's long-term debt is now $7.5M (was $3.9M) — a 94.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Protalix BioTherapeutics is outperforming or lagging.

Tracking PLX's long-term debt over time shows whether Protalix BioTherapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $7.5M That compares with $3.9M in the prior-year period — up 94.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Protalix BioTherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $7.5M) with ownership activity and broader fundamentals.

Protalix BioTherapeutics's long-term debt is $7.5M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.